APAX Apax Global Alpha

Hardman & Co Research on Apax Global Alpha (APAX): CM day: further proof of value added by Apax

Hardman & Co Research
Hardman & Co Research on Apax Global Alpha (APAX): CM day: further proof of value added by Apax

10-Jul-2024 / 10:42 GMT/BST
The issuer is solely responsible for the content of this announcement.


Hardman & Co Research on Apax Global Alpha (APAX):

CM day: further proof of value added by Apax

 

The key messages from APAX’s well-received 2024 and were: i) a new capital allocation policy with a set 11p dividend (current yield ca.7%) and creation of a distribution pool for future buybacks (if the discount is above 23%) (€30m has been seeded into pool and ); ii) the value added by the four-sector “hidden gems” strategy of buying businesses with unrealised potential at discount to peers (average 24%), improving them (average 15% increase in EBITDA growth during Apax Funds ownership), then selling at a premium (11%); and iii) the stock of exit-able businesses is rebuilding after above-normal exits in 2020-21.

 

Please click on the link below for the full report:

 

If you are interested in meeting the company, you can register your interest by clicking on the above link.

To contact us:

Hardman & Co
9 Bonhill Street

London

EC2A 4DJ

Follow us on Twitter @HardmanandCo

Contact:

Mark Thomas



 

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1943491  10-Jul-2024 

fncls.ssp?fn=show_t_gif&application_id=1943491&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
10/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apax Global Alpha

Mark Thomas
  • Mark Thomas

Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today

AGA was transparent in that 2024 was a below-average year for the company, with a total NAV return of 0.8% (-3.0% constant currency, including a 4Q total NAV return of 2.6% (-1.8% cc). By comparison, the five-year total NAV CAGR return was 8.3%. Problems in healthcare (no longer a core sector), and one portfolio company in particular, meant the strong average investee company EBITDA growth did not fuel NAV growth. However, the detail in the results bodes well, with i) investee companies deliveri...

 PRESS RELEASE

Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and...

Hardman & Co Research Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today 02-Apr-2025 / 11:39 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today   AGA was transparent in that 2024 was a below-average year for the company, with a total NAV return of 0.8% (-3.0% constant currency, including a 4Q total NAV return of 2.6% (-1.8% cc). By comparison, the five-year total NAV CAGR return was 8.3%. Problems in healthcare (...

Mark Thomas ... (+2)
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: April 2025

Feature article: 2024 pharma statistics An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024. The year was characterised by 9.2% underlying (ex-COVID-19) growth. Much of the growth was driven by recently launched ant...

Apax Global Alpha Limited: 1 director

A director at Apax Global Alpha Limited bought 15,000 shares at 134p and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Mark Thomas ... (+2)
  • Mark Thomas
  • Nigel Hawkins

Hardman & Co Monthly: March 2025

In this month's feature article, we review the energy situation in the UK. On the domestic front, Ofgem has recently announced the new price cap figure of £1,849 for a typical household’s annual use of gas and electricity; this figure represents an increase of 6.4% over the January-March 2025 price cap. UK energy policy has changed of late, following the election of a Labour government last summer. The quest for Net Zero by 2030 – a hardly realistic target – is now a priority. Rightly or wrong...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch